Salarius Pharmaceuticals (SLRX) Competitors $1.76 -0.05 (-2.49%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SLRX vs. DWTX, TXMD, BCDA, PMCB, KPRX, TLPH, BCTX, PHXM, AEON, and CYCNShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Dogwood Therapeutics (DWTX), TherapeuticsMD (TXMD), BioCardia (BCDA), PharmaCyte Biotech (PMCB), Kiora Pharmaceuticals (KPRX), Talphera (TLPH), BriaCell Therapeutics (BCTX), PHAXIAM Therapeutics (PHXM), AEON Biopharma (AEON), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Dogwood Therapeutics TherapeuticsMD BioCardia PharmaCyte Biotech Kiora Pharmaceuticals Talphera BriaCell Therapeutics PHAXIAM Therapeutics AEON Biopharma Cyclerion Therapeutics Salarius Pharmaceuticals (NASDAQ:SLRX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations. Which has more risk & volatility, SLRX or DWTX? Salarius Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Does the media prefer SLRX or DWTX? In the previous week, Salarius Pharmaceuticals and Salarius Pharmaceuticals both had 3 articles in the media. Salarius Pharmaceuticals' average media sentiment score of 1.27 beat Dogwood Therapeutics' score of 0.63 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Salarius Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, SLRX or DWTX? Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$12.54M-$8.17-0.21Dogwood TherapeuticsN/AN/A-$5.30M-$6.55-1.14 Do insiders and institutionals believe in SLRX or DWTX? 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 1.4% of Salarius Pharmaceuticals shares are owned by insiders. Comparatively, 12.2% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is SLRX or DWTX more profitable? Salarius Pharmaceuticals' return on equity of -140.28% beat Dogwood Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -140.28% -105.76% Dogwood Therapeutics N/A -217.12%-172.06% Does the MarketBeat Community believe in SLRX or DWTX? Salarius Pharmaceuticals received 26 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSalarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% Dogwood TherapeuticsN/AN/A SummarySalarius Pharmaceuticals beats Dogwood Therapeutics on 6 of the 10 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.75M$6.89B$5.69B$9.02BDividend YieldN/A2.91%5.32%4.00%P/E Ratio-0.219.2388.8019.29Price / SalesN/A307.871,019.3675.13Price / CashN/A75.4646.0938.87Price / Book0.165.485.054.99Net Income-$12.54M$123.50M$113.53M$222.83M7 Day Performance-20.91%-4.89%-1.49%-0.86%1 Month Performance11.18%-2.48%3.24%2.55%1 Year Performance-61.19%1.49%20.85%17.62% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals1.3418 of 5 stars$1.77-2.5%N/A-60.2%$2.79MN/A-0.2220Short Interest ↓Positive NewsDWTXDogwood TherapeuticsN/A$8.77-18.3%N/AN/A$11.68MN/A-1.345TXMDTherapeuticsMD1.2636 of 5 stars$1.01-1.0%N/A-56.3%$11.65M$1.60M0.00420Short Interest ↓Gap DownBCDABioCardia3.241 of 5 stars$2.37flat$25.00+954.9%-59.5%$10.86M$480,000.00-0.5740Short Interest ↑News CoverageGap DownPMCBPharmaCyte Biotech1.4504 of 5 stars$1.55+4.0%N/A-26.3%$10.80MN/A2.924Short Interest ↑Positive NewsGap DownKPRXKiora Pharmaceuticals2.9863 of 5 stars$3.60flat$10.00+177.8%-46.8%$10.80MN/A0.0010Short Interest ↑News CoverageTLPHTalphera3.3397 of 5 stars$0.63-3.1%$4.33+587.9%-32.2%$10.73M$650,000.00-0.9119Positive NewsBCTXBriaCell Therapeutics3.296 of 5 stars$3.62-2.9%$32.00+784.0%-94.2%$10.68MN/A-0.278Short Interest ↓PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AEONAEON Biopharma2.8594 of 5 stars$0.13-0.3%$5.00+3,749.1%-98.5%$10.39MN/A0.725Gap DownCYCNCyclerion Therapeutics1.3697 of 5 stars$3.82-9.3%N/A-11.5%$10.35M$1.62M0.0030Short Interest ↑Gap Down Related Companies and Tools Related Companies DWTX Competitors TXMD Competitors BCDA Competitors PMCB Competitors KPRX Competitors TLPH Competitors BCTX Competitors PHXM Competitors AEON Competitors CYCN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLRX) was last updated on 2/12/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMarket down? Do this now.The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the cl...Colonial Metals | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored$589 billion wiped out overnightYou need to watch this before you invest another cent in AI. Because more than $589 billion was wiped out o...Porter & Company | SponsoredElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.